PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 12, 2026Journal of Veterinary and Animal Sciences0 citationsOpen Access

Immunoregulatory mechanisms of mesenchymal stem cell therapy in bovine mastitis

KSKhan SharunSBShajahan Amitha BanuSMSathish Muthu

Key Points

  • The aim is to explore how mesenchymal stem cell therapy influences bovine mastitis treatment and outcomes.
  • Administration of MSCs to dairy cattle suffering from bovine mastitis.
  • Evaluation of mammary inflammation through somatic cell counts and leukocyte infiltration.
  • Assessment of clinical recovery rates and milk yield post-treatment.
  • MSCs significantly reduce inflammation, as shown by lower somatic cell counts.
  • Therapy leads to better inflammatory resolution and enhanced clinical recovery, especially in acute cases.
  • MSCs support tissue regeneration, improving milk composition and reducing fibrosis risk.

Abstract

Bovine mastitis remains a significant constraint to dairy production worldwide, resulting in substantial economic losses, animal welfare concerns and growing limitations of antimicrobial-based therapies due to antimicrobial resistance and regulatory restrictions. Mesenchymal stem cell (MSC) therapy demonstrates consistent immunomodulatory, antimicrobial and regenerative effects that directly address the complex pathophysiology of bovine mastitis. Across experimental and early clinical studies, MSC administration results in a marked reduction in mammary inflammation, reflected by decreased somatic cell counts, attenuated leukocyte infiltration and suppression of pro-inflammatory cytokines. While bacteriological cure rates vary depending on the pathogen type and disease severity, MSC therapy consistently improves inflammatory resolution and clinical recovery, particularly in cases of acute mastitis. MSC-derived paracrine factors and extracellular vesicles support epithelial regeneration, angiogenesis and extracellular matrix remodelling, leading to faster restoration of milk yield, improved milk composition and reduced risk of fibrosis. Clinical studies have reported that both autologous and allogeneic MSCs are well-tolerated in dairy cattle, with no significant local or systemic adverse effects and minimal immunogenicity. Therefore, MSC-based treatments have the potential to reduce reliance on antibiotics and eliminate milk withdrawal periods, offering clear economic and public health benefits. However, therapeutic efficacy is influenced by cell source, route of administration, dosing strategy and mastitis phenotype, underscoring the need for optimized and standardized approaches. Collectively, the available evidence demonstrates that MSC therapy delivers reproducible anti-inflammatory and regenerative benefits in bovine mastitis, representing a viable antimicrobial-sparing strategy, particularly when integrated with conventional treatments in chronic or recurrent cases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sharun et al. (2026) studied this question.

synapsesocial.com/papers/69db35be4fe01fead37c43bbhttps://doi.org/10.51966/jvas.2026.57.1.1-13
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The use of stem cells in the treatment of mastitis in dairy cows2024 · 8 citations
  2. 2Evaluation of an experimental therapy based on bovine mesenchymal stem cell (MSC) secretome for the treatment of endometritis in dairy cows2025
  3. 3Application of paracrine effect of fallopian tube stem cells derived from Holstein cattle to bovine mastitis2026
  4. 4Immunotherapy in mastitis: state of knowledge, research gaps and way forward2024 · 26 citations
  5. 5Phenotypic and Functional Characterization of Bovine Adipose-Derived Mesenchymal Stromal Cells2024 · 3 citations